The posters cover baseline traits in the phase 3 VANQUISH-2 trial and cardiometabolic measures from the phase 2 VENTURE study, November 14 to 17.
Recap by typeshit. Post by dough on X.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
The tablets would release the peptides in the colon, aimed at left-sided ulcerative colitis. Neither peptide is FDA-approved, and delivery tests so far used budesonide, not these peptides.
In an exclusive interview, the former NBA star describes the change in his life as night and day. Tap through for how he talks about it.
Loading…